(Adnkronos) - Terapia a domicilio grazie a trattamenti con farmaci stabili per un tempo più prolungato: è l’innovazione scientifica e organizzativa messa a punto da Aop Health che semplifica la somministrazione delle cure per i pazienti con Ipertensione arteriosa polmonare (Iap). Di questa novità, che riduce anche l’aggravio per le strutture sanitarie, si è parlato nel corso della conferenza stampa ‘Malattie rare.Terapia su misura e home delivery: come cambia l’approccio all’Ipertensione arteriosa polmonare’, organizzata a Palazzo dell’Informazione a Roma.
Category
🗞
NewsTranscript
00:00Hypertension of the pulmonary artery, or IAP, is a rare, progressive, severely invalidating respiratory disease, characterized by vascular resistance and therefore blood pressure, particularly high in the two branches of the pulmonary artery, which originates from the right ventricle of the heart.
00:24Conditions that determine a progressive fatigue of that ventricle, which can culminate in a cardiac or even mortal outcome.
00:31The most common symptoms of pulmonary IAP, under the category of pulmonary IAP, are fatigue, vertigo, fatigue and fainting.
00:40In Italy there are about 3,000 people who suffer from it, 2,000 in its severe form, and it strikes mostly between 30 and 60 years, precisely in that period of life in which it is particularly active.
00:52Here the need to bring patients closer to their care, making it more convenient to supply drugs thanks to a longer stability and favoring the possibility of receiving therapy at home, through a home delivery service.
01:06All with the aim of a minor aggravation for health structures.
01:10The scientific and organizational innovation of AOP Health, a global and pioneering company in integrated therapies for rare diseases and intensive care, is making this opportunity available.
01:22The intention is to try to overcome one of the many challenges for patients, families and the health system that the pulmonary arterial hypertension proposes.
01:31This has been discussed during the press conference entitled Malattie Rare, Therapy on Measure and Home Delivery Change the Approach to Pulmonary Arterial Hypertension, held in Rome at the Palazzo dell'Informazione della DNA Kronos.
01:45But what is it and how many people suffer from this pathology a little more specifically?
01:50We asked Carmine Dario Bizza, professor of cardiology at the University of Sapienza and director of cardiology at the Umberto I Polyclinic in Rome.
02:00Pulmonary arterial hypertension is a rare disease.
02:02The prevalence is in the order of 10-15 patients per million inhabitants.
02:08The idiopathic form, if we consider all the other forms together, we arrive at around 60-70 cases per million, characterized by the obstruction of the small pulmonary arteries, which progressively increase the resistance of the pulmonary circle.
02:24And so the right ventricle, which pumps blood into the lung, goes against a serious dysfunction.
02:32So it is one of the most serious and severe forms of cardiac failure that we know of.
02:37The specific causes of pulmonary arterial hypertension are almost unknown and this makes its diagnosis even more difficult.
02:46The symptoms are specific and this is the big problem of this disease.
02:50Because the most common symptom is dyspnea, fatigue.
02:55You understand that this is a symptom that is shared by all respiratory and cardiological diseases.
03:02So suspicion can be generated when a patient has dyspnea, fatigue, in the absence of a conclaimed cardiac or respiratory pathology.
03:13In this case, certifications should be made to verify if there is a pulmonary hypertension.
03:19Suffering from a rare pathology such as pulmonary arterial hypertension often means facing several concrete difficulties in terms of treatment.
03:28Currently, we have a therapeutic algorithm that involves the use of two oral drugs in patients who have a low or intermediate risk.
03:39While in patients who have a high risk, we use three drugs from the diagnosis.
03:46So two oral drugs plus a prostanoid.
03:48Prostanoids must be made in continuous infusion, either for endovenous or subcutaneous reasons.
03:57The news today is that a stability of up to 14 days has been ensured for 3 prosti.
04:06It is also expected that there will be a distribution of the drug at home and of the consumables of the device.
04:15These are important aspects because the patient will no longer have to go to the hospital pharmacy to withdraw the medicines.
04:23It seems evident, therefore, as the president of the Italian Pulmonary Hypertension Network Stefano Ghio explains,
04:30that living with pulmonary arterial hypertension is not at all simple.
04:34The first problem is that it is a rare disease, therefore little known to doctors.
04:38Therefore, a correct diagnosis, which is essential to be able to start a correct therapy, can only be achieved in an expert center of this disease.
04:49After that, the therapy can be quite complicated to perform because the most powerful and therefore most effective drugs
04:58are drugs that are supplied for endovenous or subcutaneous reasons, either in a catheter in the vein or through a needle in the subcutaneous tissue.
05:12Procedure that could be performed correctly only by going to an expert center.
05:18The news today is the delivery at home of the drug.
05:21Because let's remember that these drugs are not drugs that can be found in pharmacies, but they are hospital dispensing drugs.
05:28Therefore, the patient or caregiver must go to the hospital every month to withdraw the drug.
05:34It is a novelty that is added to other previous organizations that are useful for the patient, such as the H24 nursing service,
05:44which is made available to patients in therapy with treprostimil to help them manage the infusion site,
05:53to help them manage the change of therapy and the change of site of the needle.
05:58But what is the role of services like this in the management of diseases such as pulmonary hypertension?
06:05This organization is essentially used to bring the patient closer to the cures,
06:12because we already know that the disease is serious and invalidating,
06:16but it is a disease that imposes on the patient difficulties of living that are not indifferent.
06:23Therefore, the management of the drug, the type of drug, the arrival of the drug, the possibility of going to the reference center,
06:30which is often far away, are all conditions that alter or reduce the quality of life of the patient.
06:36And the quality of life in patients affected by chronic pathologies, such as pulmonary hypertension, is very important.